My medication was prescribed and delivered in November 2022
If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated ADVERSE REACTIONS Most common (5%) in clinical trials: injection-site nodule (10.5%), nausea (8.2%)
In the Phase 2 trial, retatrutide was administered as a once-weekly subcutaneous injection an approach consistent with other incretin-based therapies in this class
Because the medication remains active in the body for several days, a short delay in dosing usually does not immediately stop its effects
Reduced food intake and caloric restriction The primary mechanism is simple
Coaching at this phase covers training built specifically to keep muscle on you, nutrition that hits enough protein even when you dont feel like eating much, and tracking whats happening more broadly than just the scale: visible changes, strength, energy, recovery